glp 1 ras mechanism GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Glucagon-like peptide 1 receptor agonists:

The growth of GLP-1 treatment within diabetes Glucagon-like peptide 1 (GLP-1) receptor agonists have taken the healthcare world by storm, becoming one of the most successful drug classes of all time, reaching an astonishing $110 billion in sales in 2024 alone 1

According to their SmPCs, patients can inject these medications at any time of day, with or without meals, provided they maintain consistency with their chosen day of the week

Semaglutide injections remain in the bloodstream for approximately one to two weeks, while tirzepatide persists slightly longer due to its extended half-life

In studies in rodents, semaglutide caused a type of thyroid tumour, but humans have very few of the receptors involved, and large human trials havent shown a consistent increase in thyroid cancer risk